About us

partner with us

Improving the lives of patients by developing proprietary, innovative

In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Clinical trials completed and medical device certification obtained, enterprise value at EUR 180m. Exit strategy: second public offering on a selected stock exchange abroad e.g. Euronext, London Stock Exchange, alternatively a merger & acquisition deal

Our Partners

  • Merck

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Pfizer Eastern Europe

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Alcon

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Community Foundation

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

become our partner

Improving the lives of patients
by developing proprietary, innovative

Prof. Giulio Stefanini, MD, PhD, MSc

Renowned clinical and interventional cardiologist. Professor of Cardiology at Humanitas University and Head of clinical research of the Cardio Center at Humanitas Research Hospital (Milan, Italy). Holds a PhD in Experimental Medicine and a MSc in Health Economics and Management in Cardiovascular Sciences awarded by the London School of Economics and Political Sciences. Has an active role in the board of the European Association of Cardiovascular Percutaneous Interventions (EAPCI) of the European Society of Cardiology. Has authored more than 300 articles in peer-reviewed journals and has a H-index of 61.